Liraglutide is a Glucagon-Like Peptide (GLP-1) analog developed by Novo Nordisk to decrease blood sugar in patients with type 2 diabetes mellitus (T2DM) (Figure 1) (Kahal et al., 2014; Zoubek et al., 2017). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.